Table 3.
Treatment modifications and persistence on the index therapy
| Treatment modification and persistence | exBID | ExQW | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| GE LL (N = 300) | UK LL (N = 388) | FR (N = 77) | NE (N = 170) | BE (N = 845) | GE LRx (N = 4,230) | SE (N = 343) | GE LL (N = 174) | NE (N = 260) | GE LRx (N = 1,629) | SE (N = 121) | |
| Treatment modification at 180-days post-index | |||||||||||
| % no first treatment modification | 35.3 | 18.3 | 37.7 | 62.4 | 44.3 | 35.2 | 32.1 | 59.2 | 67.7 | 52.3 | 60.3 |
| % with a first treatment modification | 64.7 | 81.7 | 62.3 | 37.6 | 55.7 | 64.8 | 67.9 | 40.8 | 32.3 | 47.7 | 39.7 |
| % off-label up-titration | 12.4 | 29.3 | 8.3 | 6.3 | 4.2 | 7.4 | 18.5 | N/a | N/a | N/a | N/a |
| % down-titration | 0.0 | 12.0 | 6.3 | 1.6 | 11.3 | 19.0 | s | N/a | N/a | N/a | N/a |
| % discontinuation | 61.3 | 41.0 | 70.8 | 43.8 | 65.6 | 58.8 | 57.5 | 60.6 | 52.4 | 80.4 | 77.1 |
| % switch | 16.0 | 10.4 | 10.4 | 25.0 | 13.2 | 7.8 | 16.3 | 12.7 | 26.2 | 6.9 | s |
| % augmentation | 10.3 | 7.3 | 4.2 | 23.4 | 5.7 | 7.0 | 6.4 | 26.8 | 21.4 | 12.6 | s |
| % on-label up-titration | 5.3 | 31.7 | 6.5 | 14.7 | 26.4 | 11.9 | 25.9 | N/a | N/a | N/a | N/a |
| Persistence at 180-days post-index | |||||||||||
| % persistent | 47.0 | 54.4 | 46.8 | 73.5 | 54.9 | 52.5 | 48.7 | 69.5 | 74.6 | 57.5 | 62.8 |
| % stopped | 53.0 | 45.6 | 53.3 | 26.5 | 45.1 | 47.5 | 51.3 | 30.5 | 25.4 | 42.5 | 37.2 |
| Treatment modification and persistence | LIRA | ||||||
|---|---|---|---|---|---|---|---|
| GE LL (N = 906) | UK LL (N = 306) | FR (N = 189) | NE (N = 2,179) | BE (N = 1,384) | GE LRx (N = 12,727) | SE (N = 3,808) | |
| Treatment modification at 180-days post-index | |||||||
| % no first treatment modification | 43.8 | 43.5 | 43.4 | 63.2 | 52.0 | 51.8 | 53.7 |
| % with a first treatment modification | 56.2 | 56.5 | 56.6 | 36.8 | 48.0 | 48.2 | 46.3 |
| % off-label up-titration | 0.8 | 8.1 | 2.8 | 8.9 | 2.0 | 6.1 | 6.0 |
| % down-titration | 3.7 | 24.3 | 8.4 | 20.0 | 22.1 | 38.8 | 15.5 |
| % discontinuation | 74.7 | 53.8 | 76.6 | 48.2 | 60.1 | 30.8 | 61.3 |
| % switch | 11.4 | 7.5 | 6.5 | 9.2 | 9.6 | 5.0 | 7.0 |
| % augmentation | 9.4 | 6.4 | 5.6 | 13.7 | 6.2 | 19.4 | 10.3 |
| % on-label up-titration | 13.9 | 66.0 | 21.2 | 47.6 | 57.8 | 4.8 | 10.5 |
| Persistence at 180-days post-index | |||||||
| % persistent | 50.6 | 63.1 | 52.9 | 78.1 | 64.7 | 80.1 | 67.5 |
| % stopped | 49.4 | 36.9 | 47.1 | 21.9 | 35.3 | 19.9 | 32.5 |
Patient-level analysis was not possible with the UK LRx due to privacy legislation; therefore, treatment pattern outcomes were not assessed
N/a data not applicable, s data suppressed in Sweden due to patient count less than 10 in compliance with Swedish privacy legislation
BE Belgium, EMR Electronic Medical Records databases, exBID exenatide twice daily, exQW exenatide once weekly, FR France, GE Germany, LIRA liraglutide once daily, LRx Longitudinal Prescriptions databases, NE the Netherlands, SE Sweden, UK United Kingdom